AbCellera Biologics Inc. specializes in pioneering an advanced platform for the discovery of antibodies. This comprehensive, AI-driven system meticulously explores and analyzes natural immune systems to identify antibodies suitable for the creation of new pharmaceutical drugs. As of December 31, 2021, the company had cultivated 156 discovery programs, ranging from completed to in-progress or under contract, in partnership with 36 entities. Notably, AbCellera maintains a crucial research collaboration and license agreement with Eli Lilly and Company. Founded in 2012, the firm is headquartered in Vancouver, Canada.
Recent Q3 beat, positive ABCL635 Phase 2 data, a $200M raise, and a fresh analyst price target hike skew near-term sentiment positive, though ABCL575 discontinuation and valuation concerns temper upside.
AbCellera reported Q3 2026 EPS of -$0.13 vs. -$0.17 consensus and revenue of $10.63M vs. $6.21M expected, a wide top-line beat. The narrower loss and revenue surprise support near-term positive sentiment and validate the collaboration revenue base.
Investing.comABCL635 showed significant reductions in frequency/severity of vasomotor symptoms with favorable tolerability, and AbCellera plans late-stage development in 2027 plus expansion into cancer-treatment-induced VMS. The lead-program validation is the core driver of the recent share rally and near-term momentum.
Company Press ReleaseStoneX lifted its price target to $15 from $11 while keeping a Buy rating, citing shares having met the prior target. A higher PT from a credible firm can attract momentum buyers and reinforce the post-earnings bid.
Investing.comAbCellera completed a $200M equity offering, lifting available liquidity to roughly $890-900M. While dilutive, the strengthened balance sheet funds late-stage ABCL635 development and reduces financing risk, a net near-term positive for a clinical-stage biotech.
Company Press ReleaseDespite meeting all Phase 1 endpoints, AbCellera will not advance ABCL575 past Phase 1, citing external developments in the OX40/OX40L class. The write-off of a pipeline asset is a modest negative, though focus shifting to ABCL635 limits the damage.
Fierce BiotechFollowing an ~8.6% post-earnings move, ABCL trades near the top of its 52-week range with InvestingPro data flagging it as overvalued versus fair value. Elevated valuation and concentration risk in ABCL635 could cap near-term upside or invite profit-taking.
Investing.com